Edward Samuel
Chief Tech/Sci/R&D Officer chez ACHILLES THERAPEUTICS PLC
Profil
Edward Samuel is currently working as the SVP-Technical Operations at Achilles Therapeutics Plc.
Previously, he worked as the Director-Manufacturing at Cognate BioServices, Inc. and as the Manager-Cell Therapy Operations at Orchard Therapeutics Plc.
Dr. Samuel holds a doctorate degree from University College London and a graduate degree from King's College London.
Postes actifs de Edward Samuel
| Sociétés | Poste | Début |
|---|---|---|
| ACHILLES THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01/02/2022 |
Anciens postes connus de Edward Samuel
| Sociétés | Poste | Fin |
|---|---|---|
Cognate BioServices, Inc.
 Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Corporate Officer/Principal | - |
| ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - |
Formation de Edward Samuel
| University College London | Doctorate Degree |
| King's College London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cognate BioServices, Inc.
Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
